1	4	_	_	CD	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	Discussion	_	_	NN	_	_	_	_	_


1	Understanding	_	_	VBG	_	_	_	_	_
2	mechanisms	_	_	NNS	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	viral	_	_	JJ	_	_	_	_	_
5	strategy	_	_	NN	_	_	_	_	_
6	to	_	_	TO	_	_	_	_	_
7	evade	_	_	VB	_	_	_	_	_
8	from	_	_	IN	_	_	_	_	_
9	host	_	_	NN	_	_	_	_	_
10	antiviral	_	_	JJ	_	_	_	_	_
11	responses	_	_	NNS	_	_	_	_	_
12	is	_	_	VBZ	_	_	_	_	_
13	critical	_	_	JJ	_	_	_	_	_
14	for	_	_	IN	_	_	_	_	_
15	elucidation	_	_	NN	_	_	_	_	_
16	of	_	_	IN	_	_	_	_	_
17	the	_	_	DT	_	_	_	_	_
18	pathogenesis	_	_	NN	_	_	_	_	_
19	of	_	_	IN	_	_	_	_	_
20	CSFV	_	_	NNP	_	_	_	_	_
21	infection	_	_	NN	_	_	_	_	_
22	.	_	_	.	_	_	_	_	_


1	Type	_	_	NN	_	_	_	_	_
2	I	_	_	PRP	_	_	_	_	_
3	IFNs	_	_	NNS	_	_	_	_	_
4	represent	_	_	VBP	_	_	_	_	_
5	one	_	_	CD	_	_	_	_	_
6	of	_	_	IN	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	first	_	_	JJ	_	_	_	_	_
9	lines	_	_	NNS	_	_	_	_	_
10	of	_	_	IN	_	_	_	_	_
11	defense	_	_	NN	_	_	_	_	_
12	of	_	_	IN	_	_	_	_	_
13	the	_	_	DT	_	_	_	_	_
14	innate	_	_	JJ	_	_	_	_	_
15	immune	_	_	JJ	_	_	_	_	_
16	system	_	_	NN	_	_	_	_	_
17	and	_	_	CC	_	_	_	_	_
18	are	_	_	VBP	_	_	_	_	_
19	produced	_	_	VBN	_	_	_	_	_
20	rapidly	_	_	RB	_	_	_	_	_
21	upon	_	_	IN	_	_	_	_	_
22	recognition	_	_	NN	_	_	_	_	_
23	of	_	_	IN	_	_	_	_	_
24	viral	_	_	JJ	_	_	_	_	_
25	factors	_	_	NNS	_	_	_	_	_
26	by	_	_	IN	_	_	_	_	_
27	PRRs	_	_	NNPS	_	_	_	_	_
28	.	_	_	.	_	_	_	_	_


1	CSFV	_	_	NNP	_	_	_	_	_
2	is	_	_	VBZ	_	_	_	_	_
3	known	_	_	VBN	_	_	_	_	_
4	to	_	_	TO	_	_	_	_	_
5	interfere	_	_	VB	_	_	_	_	_
6	with	_	_	IN	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	generation	_	_	NN	_	_	_	_	_
9	of	_	_	IN	_	_	_	_	_
10	type	_	_	NN	_	_	_	_	_
11	I	_	_	PRP	_	_	_	_	_
12	IFNs	_	_	NNS	_	_	_	_	_
13	by	_	_	IN	_	_	_	_	_
14	inducing	_	_	VBG	_	_	_	_	_
15	proteasomal	_	_	JJ	_	_	_	_	_
16	degradation	_	_	NN	_	_	_	_	_
17	of	_	_	IN	_	_	_	_	_
18	IRF3	_	_	NNP	_	_	_	_	_
19	.	_	_	.	_	_	_	_	_


1	Type	_	_	NN	_	_	_	_	_
2	III	_	_	NNP	_	_	_	_	_
3	IFNs	_	_	NNP	_	_	_	_	_
4	play	_	_	VBP	_	_	_	_	_
5	a	_	_	DT	_	_	_	_	_
6	critical	_	_	JJ	_	_	_	_	_
7	role	_	_	NN	_	_	_	_	_
8	in	_	_	IN	_	_	_	_	_
9	antiviral	_	_	JJ	_	_	_	_	_
10	innate	_	_	JJ	_	_	_	_	_
11	immunity	_	_	NN	_	_	_	_	_
12	in	_	_	IN	_	_	_	_	_
13	mucosal	_	_	JJ	_	_	_	_	_
14	epithelial	_	_	JJ	_	_	_	_	_
15	cells	_	_	NNS	_	_	_	_	_
16	.	_	_	.	_	_	_	_	_


1	However	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	little	_	_	JJ	_	_	_	_	_
4	information	_	_	NN	_	_	_	_	_
5	is	_	_	VBZ	_	_	_	_	_
6	available	_	_	JJ	_	_	_	_	_
7	as	_	_	IN	_	_	_	_	_
8	to	_	_	TO	_	_	_	_	_
9	whether	_	_	IN	_	_	_	_	_
10	and	_	_	CC	_	_	_	_	_
11	how	_	_	WRB	_	_	_	_	_
12	CSFV	_	_	NNP	_	_	_	_	_
13	modulates	_	_	VBZ	_	_	_	_	_
14	type	_	_	NN	_	_	_	_	_
15	III	_	_	CD	_	_	_	_	_
16	IFN	_	_	NN	_	_	_	_	_
17	response	_	_	NN	_	_	_	_	_
18	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	present	_	_	JJ	_	_	_	_	_
3	study	_	_	NN	_	_	_	_	_
4	demonstrates	_	_	VBZ	_	_	_	_	_
5	that	_	_	IN	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	Npro	_	_	NNP	_	_	_	_	_
8	protein	_	_	NN	_	_	_	_	_
9	of	_	_	IN	_	_	_	_	_
10	CSFV	_	_	NNP	_	_	_	_	_
11	inhibited	_	_	VBD	_	_	_	_	_
12	IRF1-mediated	_	_	JJ	_	_	_	_	_
13	type	_	_	NN	_	_	_	_	_
14	III	_	_	CD	_	_	_	_	_
15	IFNs	_	_	NNS	_	_	_	_	_
16	production	_	_	NN	_	_	_	_	_
17	by	_	_	IN	_	_	_	_	_
18	down-regulation	_	_	NN	_	_	_	_	_
19	of	_	_	IN	_	_	_	_	_
20	IRF1	_	_	NN	_	_	_	_	_
21	expression	_	_	NN	_	_	_	_	_
22	and	_	_	CC	_	_	_	_	_
23	blockage	_	_	NN	_	_	_	_	_
24	of	_	_	IN	_	_	_	_	_
25	its	_	_	PRP$	_	_	_	_	_
26	nuclear	_	_	JJ	_	_	_	_	_
27	translocation	_	_	NN	_	_	_	_	_
28	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	Npro-deleted	_	_	JJ	_	_	_	_	_
3	mutant	_	_	NN	_	_	_	_	_
4	showed	_	_	VBD	_	_	_	_	_
5	similar	_	_	JJ	_	_	_	_	_
6	growth	_	_	NN	_	_	_	_	_
7	kinetics	_	_	NNS	_	_	_	_	_
8	to	_	_	TO	_	_	_	_	_
9	its	_	_	PRP$	_	_	_	_	_
10	parental	_	_	JJ	_	_	_	_	_
11	strain	_	_	NN	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	indicating	_	_	VBG	_	_	_	_	_
14	that	_	_	IN	_	_	_	_	_
15	CSFV	_	_	NNP	_	_	_	_	_
16	Npro	_	_	NNP	_	_	_	_	_
17	does	_	_	VBZ	_	_	_	_	_
18	not	_	_	RB	_	_	_	_	_
19	alter	_	_	VB	_	_	_	_	_
20	the	_	_	DT	_	_	_	_	_
21	replication	_	_	NN	_	_	_	_	_
22	in	_	_	IN	_	_	_	_	_
23	cell	_	_	NN	_	_	_	_	_
24	culture	_	_	NN	_	_	_	_	_
25	,	_	_	,	_	_	_	_	_
26	which	_	_	WDT	_	_	_	_	_
27	is	_	_	VBZ	_	_	_	_	_
28	consistent	_	_	JJ	_	_	_	_	_
29	with	_	_	IN	_	_	_	_	_
30	the	_	_	DT	_	_	_	_	_
31	previous	_	_	JJ	_	_	_	_	_
32	study	_	_	NN	_	_	_	_	_
33	.	_	_	.	_	_	_	_	_


1	Some	_	_	DT	_	_	_	_	_
2	viruses	_	_	NNS	_	_	_	_	_
3	have	_	_	VBP	_	_	_	_	_
4	evolved	_	_	VBN	_	_	_	_	_
5	to	_	_	TO	_	_	_	_	_
6	encode	_	_	VB	_	_	_	_	_
7	viral	_	_	JJ	_	_	_	_	_
8	antagonists	_	_	NNS	_	_	_	_	_
9	for	_	_	IN	_	_	_	_	_
10	evasion	_	_	NN	_	_	_	_	_
11	of	_	_	IN	_	_	_	_	_
12	type	_	_	NN	_	_	_	_	_
13	III	_	_	CD	_	_	_	_	_
14	IFNs	_	_	NN	_	_	_	_	_
15	responses	_	_	NNS	_	_	_	_	_
16	.	_	_	.	_	_	_	_	_


1	Reid	_	_	NNP	_	_	_	_	_
2	et	_	_	NNP	_	_	_	_	_
3	al	_	_	NNP	_	_	_	_	_
4	showed	_	_	VBD	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	induction	_	_	NN	_	_	_	_	_
7	of	_	_	IN	_	_	_	_	_
8	type	_	_	NN	_	_	_	_	_
9	III	_	_	CD	_	_	_	_	_
10	IFNs	_	_	NNS	_	_	_	_	_
11	in	_	_	IN	_	_	_	_	_
12	pDCs	_	_	NNS	_	_	_	_	_
13	upon	_	_	IN	_	_	_	_	_
14	BVDV	_	_	NNP	_	_	_	_	_
15	infection	_	_	NN	_	_	_	_	_
16	,	_	_	,	_	_	_	_	_
17	and	_	_	CC	_	_	_	_	_
18	type	_	_	NN	_	_	_	_	_
19	III	_	_	CD	_	_	_	_	_
20	IFNs	_	_	NNS	_	_	_	_	_
21	contributed	_	_	VBD	_	_	_	_	_
22	to	_	_	TO	_	_	_	_	_
23	suppression	_	_	NN	_	_	_	_	_
24	of	_	_	IN	_	_	_	_	_
25	cellular	_	_	JJ	_	_	_	_	_
26	immune	_	_	JJ	_	_	_	_	_
27	response	_	_	NN	_	_	_	_	_
28	during	_	_	IN	_	_	_	_	_
29	BVDV	_	_	NNP	_	_	_	_	_
30	infection	_	_	NN	_	_	_	_	_
31	.	_	_	.	_	_	_	_	_
32	Cai	_	_	NNP	_	_	_	_	_
33	et	_	_	FW	_	_	_	_	_
34	al	_	_	FW	_	_	_	_	_
35	shows	_	_	VBZ	_	_	_	_	_
36	that	_	_	IN	_	_	_	_	_
37	CSFV	_	_	NNP	_	_	_	_	_
38	induced	_	_	VBD	_	_	_	_	_
39	the	_	_	DT	_	_	_	_	_
40	expression	_	_	NN	_	_	_	_	_
41	of	_	_	IN	_	_	_	_	_
42	type	_	_	NN	_	_	_	_	_
43	III	_	_	NN	_	_	_	_	_
44	IFNs	_	_	NNS	_	_	_	_	_
45	in	_	_	IN	_	_	_	_	_
46	PK-15	_	_	NNP	_	_	_	_	_
47	cells	_	_	NNS	_	_	_	_	_
48	,	_	_	,	_	_	_	_	_
49	but	_	_	CC	_	_	_	_	_
50	with	_	_	IN	_	_	_	_	_
51	a	_	_	DT	_	_	_	_	_
52	limited	_	_	JJ	_	_	_	_	_
53	level	_	_	NN	_	_	_	_	_
54	of	_	_	IN	_	_	_	_	_
55	increase	_	_	NN	_	_	_	_	_
56	,	_	_	,	_	_	_	_	_
57	suggesting	_	_	VBG	_	_	_	_	_
58	that	_	_	IN	_	_	_	_	_
59	CSFV	_	_	NNP	_	_	_	_	_
60	might	_	_	MD	_	_	_	_	_
61	have	_	_	VB	_	_	_	_	_
62	a	_	_	DT	_	_	_	_	_
63	strategy	_	_	NN	_	_	_	_	_
64	to	_	_	TO	_	_	_	_	_
65	suppress	_	_	VB	_	_	_	_	_
66	expression	_	_	NN	_	_	_	_	_
67	of	_	_	IN	_	_	_	_	_
68	type	_	_	NN	_	_	_	_	_
69	III	_	_	CD	_	_	_	_	_
70	IFNs	_	_	NNS	_	_	_	_	_
71	.	_	_	.	_	_	_	_	_


1	We	_	_	PRP	_	_	_	_	_
2	also	_	_	RB	_	_	_	_	_
3	found	_	_	VBD	_	_	_	_	_
4	limited	_	_	JJ	_	_	_	_	_
5	up-regulation	_	_	NN	_	_	_	_	_
6	of	_	_	IN	_	_	_	_	_
7	type	_	_	NN	_	_	_	_	_
8	III	_	_	CD	_	_	_	_	_
9	IFNs	_	_	NNS	_	_	_	_	_
10	transcription	_	_	NN	_	_	_	_	_
11	upon	_	_	IN	_	_	_	_	_
12	wtCSFV	_	_	NN	_	_	_	_	_
13	infection	_	_	NN	_	_	_	_	_
14	in	_	_	IN	_	_	_	_	_
15	IPEC-J2	_	_	NNP	_	_	_	_	_
16	cells	_	_	NNS	_	_	_	_	_
17	,	_	_	,	_	_	_	_	_
18	though	_	_	IN	_	_	_	_	_
19	the	_	_	DT	_	_	_	_	_
20	transcription	_	_	NN	_	_	_	_	_
21	level	_	_	NN	_	_	_	_	_
22	peaked	_	_	VBD	_	_	_	_	_
23	at	_	_	IN	_	_	_	_	_
24	24	_	_	CD	_	_	_	_	_
25	hpi	_	_	NN	_	_	_	_	_
26	and	_	_	CC	_	_	_	_	_
27	decreased	_	_	VBD	_	_	_	_	_
28	thereafter	_	_	RB	_	_	_	_	_
29	,	_	_	,	_	_	_	_	_
30	which	_	_	WDT	_	_	_	_	_
31	is	_	_	VBZ	_	_	_	_	_
32	different	_	_	JJ	_	_	_	_	_
33	from	_	_	IN	_	_	_	_	_
34	the	_	_	DT	_	_	_	_	_
35	results	_	_	NNS	_	_	_	_	_
36	shown	_	_	VBN	_	_	_	_	_
37	by	_	_	IN	_	_	_	_	_
38	Cai	_	_	NNP	_	_	_	_	_
39	et	_	_	FW	_	_	_	_	_
40	al	_	_	FW	_	_	_	_	_
41	that	_	_	IN	_	_	_	_	_
42	the	_	_	DT	_	_	_	_	_
43	mRNA	_	_	NNP	_	_	_	_	_
44	level	_	_	NN	_	_	_	_	_
45	of	_	_	IN	_	_	_	_	_
46	IFN-λ1	_	_	NNP	_	_	_	_	_
47	and	_	_	CC	_	_	_	_	_
48	IFN-λ3	_	_	NNP	_	_	_	_	_
49	induced	_	_	VBN	_	_	_	_	_
50	by	_	_	IN	_	_	_	_	_
51	wtCSFV	_	_	NNP	_	_	_	_	_
52	peaked	_	_	VBD	_	_	_	_	_
53	at	_	_	IN	_	_	_	_	_
54	36	_	_	CD	_	_	_	_	_
55	and	_	_	CC	_	_	_	_	_
56	48	_	_	CD	_	_	_	_	_
57	hpi	_	_	NN	_	_	_	_	_
58	,	_	_	,	_	_	_	_	_
59	respectively	_	_	RB	_	_	_	_	_
60	.	_	_	.	_	_	_	_	_


1	We	_	_	PRP	_	_	_	_	_
2	speculate	_	_	VBP	_	_	_	_	_
3	that	_	_	IN	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	difference	_	_	NN	_	_	_	_	_
6	might	_	_	MD	_	_	_	_	_
7	be	_	_	VB	_	_	_	_	_
8	due	_	_	JJ	_	_	_	_	_
9	to	_	_	TO	_	_	_	_	_
10	different	_	_	JJ	_	_	_	_	_
11	cell	_	_	NN	_	_	_	_	_
12	types	_	_	NNS	_	_	_	_	_
13	used	_	_	VBN	_	_	_	_	_
14	.	_	_	.	_	_	_	_	_


1	Because	_	_	IN	_	_	_	_	_
2	CSFV	_	_	NNP	_	_	_	_	_
3	causes	_	_	VBZ	_	_	_	_	_
4	enteric	_	_	JJ	_	_	_	_	_
5	pathologies	_	_	NNS	_	_	_	_	_
6	,	_	_	,	_	_	_	_	_
7	a	_	_	DT	_	_	_	_	_
8	cell	_	_	NN	_	_	_	_	_
9	line	_	_	NN	_	_	_	_	_
10	from	_	_	IN	_	_	_	_	_
11	the	_	_	DT	_	_	_	_	_
12	intestines	_	_	NNS	_	_	_	_	_
13	could	_	_	MD	_	_	_	_	_
14	be	_	_	VB	_	_	_	_	_
15	a	_	_	DT	_	_	_	_	_
16	good	_	_	JJ	_	_	_	_	_
17	choice	_	_	NN	_	_	_	_	_
18	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	IPEC-J2	_	_	NNP	_	_	_	_	_
3	cell	_	_	NN	_	_	_	_	_
4	line	_	_	NN	_	_	_	_	_
5	was	_	_	VBD	_	_	_	_	_
6	from	_	_	IN	_	_	_	_	_
7	non-transformed	_	_	JJ	_	_	_	_	_
8	cells	_	_	NNS	_	_	_	_	_
9	collected	_	_	VBN	_	_	_	_	_
10	from	_	_	IN	_	_	_	_	_
11	the	_	_	DT	_	_	_	_	_
12	jejunum	_	_	NN	_	_	_	_	_
13	of	_	_	IN	_	_	_	_	_
14	a	_	_	DT	_	_	_	_	_
15	neonatal	_	_	JJ	_	_	_	_	_
16	piglet	_	_	NN	_	_	_	_	_
17	and	_	_	CC	_	_	_	_	_
18	suitable	_	_	JJ	_	_	_	_	_
19	for	_	_	IN	_	_	_	_	_
20	infection	_	_	NN	_	_	_	_	_
21	studies	_	_	NNS	_	_	_	_	_
22	for	_	_	IN	_	_	_	_	_
23	enteropathogens	_	_	NNS	_	_	_	_	_
24	.	_	_	.	_	_	_	_	_


1	IPEC-J2	_	_	NNP	_	_	_	_	_
2	exhibited	_	_	VBD	_	_	_	_	_
3	robust	_	_	JJ	_	_	_	_	_
4	expression	_	_	NN	_	_	_	_	_
5	of	_	_	IN	_	_	_	_	_
6	type	_	_	NN	_	_	_	_	_
7	III	_	_	NN	_	_	_	_	_
8	IFNs	_	_	NNS	_	_	_	_	_
9	with	_	_	IN	_	_	_	_	_
10	a	_	_	DT	_	_	_	_	_
11	relatively	_	_	RB	_	_	_	_	_
12	lower	_	_	JJR	_	_	_	_	_
13	type	_	_	NN	_	_	_	_	_
14	I	_	_	PRP	_	_	_	_	_
15	IFNs	_	_	NNS	_	_	_	_	_
16	response	_	_	NN	_	_	_	_	_
17	.	_	_	.	_	_	_	_	_


1	Thus	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	IPEC-J2	_	_	NNP	_	_	_	_	_
5	cell	_	_	NN	_	_	_	_	_
6	line	_	_	NN	_	_	_	_	_
7	was	_	_	VBD	_	_	_	_	_
8	chosen	_	_	VBN	_	_	_	_	_
9	in	_	_	IN	_	_	_	_	_
10	this	_	_	DT	_	_	_	_	_
11	study	_	_	NN	_	_	_	_	_
12	.	_	_	.	_	_	_	_	_


1	Cell	_	_	NN	_	_	_	_	_
2	lines	_	_	NNS	_	_	_	_	_
3	or	_	_	CC	_	_	_	_	_
4	primary	_	_	JJ	_	_	_	_	_
5	cultures	_	_	NNS	_	_	_	_	_
6	from	_	_	IN	_	_	_	_	_
7	other	_	_	JJ	_	_	_	_	_
8	intestinal	_	_	JJ	_	_	_	_	_
9	areas	_	_	NNS	_	_	_	_	_
10	or	_	_	CC	_	_	_	_	_
11	from	_	_	IN	_	_	_	_	_
12	adult	_	_	JJ	_	_	_	_	_
13	pigs	_	_	NNS	_	_	_	_	_
14	could	_	_	MD	_	_	_	_	_
15	be	_	_	VB	_	_	_	_	_
16	approached	_	_	VBN	_	_	_	_	_
17	for	_	_	IN	_	_	_	_	_
18	further	_	_	JJR	_	_	_	_	_
19	investigation	_	_	NN	_	_	_	_	_
20	of	_	_	IN	_	_	_	_	_
21	the	_	_	DT	_	_	_	_	_
22	interactions	_	_	NNS	_	_	_	_	_
23	between	_	_	IN	_	_	_	_	_
24	CSFV	_	_	NNP	_	_	_	_	_
25	and	_	_	CC	_	_	_	_	_
26	type	_	_	NN	_	_	_	_	_
27	III	_	_	NNP	_	_	_	_	_
28	IFNs	_	_	NNP	_	_	_	_	_
29	.	_	_	.	_	_	_	_	_


1	We	_	_	PRP	_	_	_	_	_
2	found	_	_	VBD	_	_	_	_	_
3	that	_	_	IN	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	∆Npro	_	_	JJ	_	_	_	_	_
6	mutant	_	_	NN	_	_	_	_	_
7	induced	_	_	VBD	_	_	_	_	_
8	significantly	_	_	RB	_	_	_	_	_
9	higher	_	_	JJR	_	_	_	_	_
10	transcription	_	_	NN	_	_	_	_	_
11	of	_	_	IN	_	_	_	_	_
12	IFNs	_	_	NNS	_	_	_	_	_
13	in	_	_	IN	_	_	_	_	_
14	IPEC-J2	_	_	NNP	_	_	_	_	_
15	cells	_	_	NNS	_	_	_	_	_
16	from	_	_	IN	_	_	_	_	_
17	24	_	_	CD	_	_	_	_	_
18	to	_	_	TO	_	_	_	_	_
19	48	_	_	CD	_	_	_	_	_
20	hpi	_	_	NN	_	_	_	_	_
21	than	_	_	IN	_	_	_	_	_
22	its	_	_	PRP$	_	_	_	_	_
23	parental	_	_	JJ	_	_	_	_	_
24	strain	_	_	NN	_	_	_	_	_
25	,	_	_	,	_	_	_	_	_
26	suggesting	_	_	VBG	_	_	_	_	_
27	that	_	_	IN	_	_	_	_	_
28	the	_	_	DT	_	_	_	_	_
29	Npro	_	_	NNP	_	_	_	_	_
30	protein	_	_	NN	_	_	_	_	_
31	might	_	_	MD	_	_	_	_	_
32	be	_	_	VB	_	_	_	_	_
33	antagonistic	_	_	JJ	_	_	_	_	_
34	to	_	_	TO	_	_	_	_	_
35	expression	_	_	NN	_	_	_	_	_
36	of	_	_	IN	_	_	_	_	_
37	type	_	_	NN	_	_	_	_	_
38	III	_	_	CD	_	_	_	_	_
39	IFNs	_	_	NNS	_	_	_	_	_
40	.	_	_	.	_	_	_	_	_


1	Because	_	_	IN	_	_	_	_	_
2	CSFV	_	_	NNP	_	_	_	_	_
3	Npro	_	_	NNP	_	_	_	_	_
4	has	_	_	VBZ	_	_	_	_	_
5	been	_	_	VBN	_	_	_	_	_
6	found	_	_	VBN	_	_	_	_	_
7	to	_	_	TO	_	_	_	_	_
8	subvert	_	_	VB	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	type	_	_	NN	_	_	_	_	_
11	I	_	_	PRP	_	_	_	_	_
12	IFN	_	_	NNP	_	_	_	_	_
13	response	_	_	NN	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	we	_	_	PRP	_	_	_	_	_
16	speculated	_	_	VBD	_	_	_	_	_
17	if	_	_	IN	_	_	_	_	_
18	Npro	_	_	NNP	_	_	_	_	_
19	might	_	_	MD	_	_	_	_	_
20	have	_	_	VB	_	_	_	_	_
21	similar	_	_	JJ	_	_	_	_	_
22	effect	_	_	NN	_	_	_	_	_
23	on	_	_	IN	_	_	_	_	_
24	type	_	_	NN	_	_	_	_	_
25	III	_	_	NNP	_	_	_	_	_
26	IFNs	_	_	NNP	_	_	_	_	_
27	.	_	_	.	_	_	_	_	_


1	We	_	_	PRP	_	_	_	_	_
2	showed	_	_	VBD	_	_	_	_	_
3	that	_	_	IN	_	_	_	_	_
4	wtCSFV	_	_	NNP	_	_	_	_	_
5	strongly	_	_	RB	_	_	_	_	_
6	inhibited	_	_	VBN	_	_	_	_	_
7	expression	_	_	NN	_	_	_	_	_
8	of	_	_	IN	_	_	_	_	_
9	poly(I	_	_	NN	_	_	_	_	_
10	:	_	_	:	_	_	_	_	_
11	C)-induced	_	_	JJ	_	_	_	_	_
12	type	_	_	NN	_	_	_	_	_
13	III	_	_	CD	_	_	_	_	_
14	IFNs	_	_	NNS	_	_	_	_	_
15	in	_	_	IN	_	_	_	_	_
16	IPEC-J2	_	_	NNP	_	_	_	_	_
17	cells	_	_	NNS	_	_	_	_	_
18	and	_	_	CC	_	_	_	_	_
19	Npro	_	_	NNP	_	_	_	_	_
20	deletion	_	_	NN	_	_	_	_	_
21	abolished	_	_	VBD	_	_	_	_	_
22	such	_	_	PDT	_	_	_	_	_
23	an	_	_	DT	_	_	_	_	_
24	inhibitory	_	_	JJ	_	_	_	_	_
25	effect	_	_	NN	_	_	_	_	_
26	.	_	_	.	_	_	_	_	_


1	We	_	_	PRP	_	_	_	_	_
2	further	_	_	RBR	_	_	_	_	_
3	showed	_	_	VBD	_	_	_	_	_
4	that	_	_	IN	_	_	_	_	_
5	Npro	_	_	NNP	_	_	_	_	_
6	over-expression	_	_	NN	_	_	_	_	_
7	led	_	_	VBD	_	_	_	_	_
8	to	_	_	TO	_	_	_	_	_
9	a	_	_	DT	_	_	_	_	_
10	marked	_	_	VBN	_	_	_	_	_
11	reduction	_	_	NN	_	_	_	_	_
12	of	_	_	IN	_	_	_	_	_
13	mRNA	_	_	NN	_	_	_	_	_
14	transcripts	_	_	NNS	_	_	_	_	_
15	of	_	_	IN	_	_	_	_	_
16	type	_	_	NN	_	_	_	_	_
17	III	_	_	NNP	_	_	_	_	_
18	IFNs	_	_	NNP	_	_	_	_	_
19	.	_	_	.	_	_	_	_	_


1	Either	_	_	CC	_	_	_	_	_
2	infection	_	_	NN	_	_	_	_	_
3	with	_	_	IN	_	_	_	_	_
4	wtCSFV	_	_	NN	_	_	_	_	_
5	or	_	_	CC	_	_	_	_	_
6	over-expression	_	_	NN	_	_	_	_	_
7	of	_	_	IN	_	_	_	_	_
8	Npro	_	_	NNP	_	_	_	_	_
9	also	_	_	RB	_	_	_	_	_
10	resulted	_	_	VBD	_	_	_	_	_
11	in	_	_	IN	_	_	_	_	_
12	significant	_	_	JJ	_	_	_	_	_
13	reduction	_	_	NN	_	_	_	_	_
14	of	_	_	IN	_	_	_	_	_
15	the	_	_	DT	_	_	_	_	_
16	IFN-λ3	_	_	NN	_	_	_	_	_
17	promoter	_	_	NN	_	_	_	_	_
18	activity	_	_	NN	_	_	_	_	_
19	of	_	_	IN	_	_	_	_	_
20	poly(I	_	_	NN	_	_	_	_	_
21	:	_	_	:	_	_	_	_	_
22	C)-treated	_	_	VBN	_	_	_	_	_
23	IPEC-J2	_	_	NN	_	_	_	_	_
24	cells	_	_	NNS	_	_	_	_	_
25	.	_	_	.	_	_	_	_	_


1	These	_	_	DT	_	_	_	_	_
2	results	_	_	NNS	_	_	_	_	_
3	demonstrate	_	_	VBP	_	_	_	_	_
4	that	_	_	IN	_	_	_	_	_
5	CSFV	_	_	NNP	_	_	_	_	_
6	employs	_	_	VBZ	_	_	_	_	_
7	its	_	_	PRP$	_	_	_	_	_
8	Npro	_	_	NNP	_	_	_	_	_
9	to	_	_	TO	_	_	_	_	_
10	inhibit	_	_	VB	_	_	_	_	_
11	type	_	_	NN	_	_	_	_	_
12	III	_	_	CD	_	_	_	_	_
13	IFNs	_	_	NNS	_	_	_	_	_
14	expression	_	_	NN	_	_	_	_	_
15	probably	_	_	RB	_	_	_	_	_
16	by	_	_	IN	_	_	_	_	_
17	targeting	_	_	VBG	_	_	_	_	_
18	the	_	_	DT	_	_	_	_	_
19	regulatory	_	_	JJ	_	_	_	_	_
20	elements	_	_	NNS	_	_	_	_	_
21	involved	_	_	VBN	_	_	_	_	_
22	in	_	_	IN	_	_	_	_	_
23	transcription	_	_	NN	_	_	_	_	_
24	of	_	_	IN	_	_	_	_	_
25	IFN-λs	_	_	NNP	_	_	_	_	_
26	.	_	_	.	_	_	_	_	_


1	Activation	_	_	NN	_	_	_	_	_
2	of	_	_	IN	_	_	_	_	_
3	type	_	_	NN	_	_	_	_	_
4	III	_	_	CD	_	_	_	_	_
5	IFNs	_	_	NNS	_	_	_	_	_
6	,	_	_	,	_	_	_	_	_
7	as	_	_	IN	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	case	_	_	NN	_	_	_	_	_
10	with	_	_	IN	_	_	_	_	_
11	type	_	_	NN	_	_	_	_	_
12	I	_	_	PRP	_	_	_	_	_
13	IFNs	_	_	NNS	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	requires	_	_	VBZ	_	_	_	_	_
16	IRF3	_	_	NNP	_	_	_	_	_
17	,	_	_	,	_	_	_	_	_
18	IRF7	_	_	NNP	_	_	_	_	_
19	and	_	_	CC	_	_	_	_	_
20	NF-κB	_	_	NNP	_	_	_	_	_
21	.	_	_	.	_	_	_	_	_


1	However	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	expression	_	_	NN	_	_	_	_	_
4	of	_	_	IN	_	_	_	_	_
5	type	_	_	NN	_	_	_	_	_
6	III	_	_	NNP	_	_	_	_	_
7	IFNs	_	_	NNP	_	_	_	_	_
8	does	_	_	VBZ	_	_	_	_	_
9	not	_	_	RB	_	_	_	_	_
10	need	_	_	VB	_	_	_	_	_
11	all	_	_	DT	_	_	_	_	_
12	components	_	_	NNS	_	_	_	_	_
13	of	_	_	IN	_	_	_	_	_
14	the	_	_	DT	_	_	_	_	_
15	enhanceosome	_	_	NN	_	_	_	_	_
16	.	_	_	.	_	_	_	_	_


1	IRF1	_	_	NNP	_	_	_	_	_
2	is	_	_	VBZ	_	_	_	_	_
3	a	_	_	DT	_	_	_	_	_
4	predominant	_	_	JJ	_	_	_	_	_
5	antiviral	_	_	JJ	_	_	_	_	_
6	molecule	_	_	NN	_	_	_	_	_
7	against	_	_	IN	_	_	_	_	_
8	many	_	_	JJ	_	_	_	_	_
9	viruses	_	_	NNS	_	_	_	_	_
10	.	_	_	.	_	_	_	_	_


1	It	_	_	PRP	_	_	_	_	_
2	is	_	_	VBZ	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	first	_	_	JJ	_	_	_	_	_
5	identified	_	_	VBN	_	_	_	_	_
6	member	_	_	NN	_	_	_	_	_
7	of	_	_	IN	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	IRF	_	_	NNP	_	_	_	_	_
10	family	_	_	NN	_	_	_	_	_
11	,	_	_	,	_	_	_	_	_
12	but	_	_	CC	_	_	_	_	_
13	it	_	_	PRP	_	_	_	_	_
14	does	_	_	VBZ	_	_	_	_	_
15	not	_	_	RB	_	_	_	_	_
16	induce	_	_	VB	_	_	_	_	_
17	production	_	_	NN	_	_	_	_	_
18	of	_	_	IN	_	_	_	_	_
19	type	_	_	NN	_	_	_	_	_
20	I	_	_	PRP	_	_	_	_	_
21	IFNs	_	_	NNS	_	_	_	_	_
22	.	_	_	.	_	_	_	_	_
23	Odendall	_	_	NNP	_	_	_	_	_
24	et	_	_	FW	_	_	_	_	_
25	al	_	_	NNP	_	_	_	_	_
26	has	_	_	VBZ	_	_	_	_	_
27	shown	_	_	VBN	_	_	_	_	_
28	that	_	_	IN	_	_	_	_	_
29	IRF1	_	_	NNP	_	_	_	_	_
30	regulates	_	_	VBZ	_	_	_	_	_
31	peroxisome-mediated	_	_	JJ	_	_	_	_	_
32	IFN-λ1	_	_	NN	_	_	_	_	_
33	expression	_	_	NN	_	_	_	_	_
34	.	_	_	.	_	_	_	_	_


1	Epithelial	_	_	JJ	_	_	_	_	_
2	cells	_	_	NNS	_	_	_	_	_
3	have	_	_	VBP	_	_	_	_	_
4	preference	_	_	NN	_	_	_	_	_
5	of	_	_	IN	_	_	_	_	_
6	producing	_	_	VBG	_	_	_	_	_
7	IFN-λs	_	_	NNS	_	_	_	_	_
8	over	_	_	IN	_	_	_	_	_
9	IFN-α/β	_	_	NNP	_	_	_	_	_
10	upon	_	_	IN	_	_	_	_	_
11	viral	_	_	JJ	_	_	_	_	_
12	infection	_	_	NN	_	_	_	_	_
13	.	_	_	.	_	_	_	_	_


1	This	_	_	DT	_	_	_	_	_
2	may	_	_	MD	_	_	_	_	_
3	be	_	_	VB	_	_	_	_	_
4	due	_	_	JJ	_	_	_	_	_
5	to	_	_	TO	_	_	_	_	_
6	relatively	_	_	RB	_	_	_	_	_
7	higher	_	_	JJR	_	_	_	_	_
8	expression	_	_	NN	_	_	_	_	_
9	of	_	_	IN	_	_	_	_	_
10	peroxisomes	_	_	NNS	_	_	_	_	_
11	in	_	_	IN	_	_	_	_	_
12	epithelial	_	_	JJ	_	_	_	_	_
13	cells	_	_	NNS	_	_	_	_	_
14	.	_	_	.	_	_	_	_	_


1	Peroxisomal	_	_	NNP	_	_	_	_	_
2	MAVS	_	_	NNP	_	_	_	_	_
3	is	_	_	VBZ	_	_	_	_	_
4	known	_	_	VBN	_	_	_	_	_
5	to	_	_	TO	_	_	_	_	_
6	induce	_	_	VB	_	_	_	_	_
7	type	_	_	NN	_	_	_	_	_
8	III	_	_	NNP	_	_	_	_	_
9	IFNs	_	_	NNP	_	_	_	_	_
10	,	_	_	,	_	_	_	_	_
11	as	_	_	IN	_	_	_	_	_
12	opposed	_	_	VBN	_	_	_	_	_
13	to	_	_	TO	_	_	_	_	_
14	induction	_	_	NN	_	_	_	_	_
15	of	_	_	IN	_	_	_	_	_
16	type	_	_	NN	_	_	_	_	_
17	I	_	_	PRP	_	_	_	_	_
18	IFNs	_	_	NNS	_	_	_	_	_
19	via	_	_	IN	_	_	_	_	_
20	mitochondrial	_	_	JJ	_	_	_	_	_
21	MAVS	_	_	NNP	_	_	_	_	_
22	.	_	_	.	_	_	_	_	_


1	To	_	_	TO	_	_	_	_	_
2	better	_	_	RBR	_	_	_	_	_
3	understand	_	_	VB	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	regulation	_	_	NN	_	_	_	_	_
6	of	_	_	IN	_	_	_	_	_
7	type	_	_	NN	_	_	_	_	_
8	III	_	_	CD	_	_	_	_	_
9	IFNs	_	_	NNS	_	_	_	_	_
10	by	_	_	IN	_	_	_	_	_
11	IRF1	_	_	NNP	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	we	_	_	PRP	_	_	_	_	_
14	attempted	_	_	VBD	_	_	_	_	_
15	to	_	_	TO	_	_	_	_	_
16	regulate	_	_	VB	_	_	_	_	_
17	levels	_	_	NNS	_	_	_	_	_
18	of	_	_	IN	_	_	_	_	_
19	IRF1	_	_	NN	_	_	_	_	_
20	expression	_	_	NN	_	_	_	_	_
21	by	_	_	IN	_	_	_	_	_
22	overexpression	_	_	NN	_	_	_	_	_
23	or	_	_	CC	_	_	_	_	_
24	RNA	_	_	NN	_	_	_	_	_
25	interference	_	_	NN	_	_	_	_	_
26	in	_	_	IN	_	_	_	_	_
27	IPEC-J2	_	_	NNP	_	_	_	_	_
28	cells	_	_	NNS	_	_	_	_	_
29	.	_	_	.	_	_	_	_	_


1	Overexpression	_	_	NN	_	_	_	_	_
2	of	_	_	IN	_	_	_	_	_
3	IRF1	_	_	NNP	_	_	_	_	_
4	led	_	_	VBD	_	_	_	_	_
5	to	_	_	TO	_	_	_	_	_
6	a	_	_	DT	_	_	_	_	_
7	significant	_	_	JJ	_	_	_	_	_
8	increase	_	_	NN	_	_	_	_	_
9	of	_	_	IN	_	_	_	_	_
10	transcription	_	_	NN	_	_	_	_	_
11	of	_	_	IN	_	_	_	_	_
12	all	_	_	DT	_	_	_	_	_
13	IFN-λs	_	_	NNS	_	_	_	_	_
14	and	_	_	CC	_	_	_	_	_
15	IFN-λ3	_	_	NNP	_	_	_	_	_
16	promoter	_	_	NN	_	_	_	_	_
17	activity	_	_	NN	_	_	_	_	_
18	,	_	_	,	_	_	_	_	_
19	while	_	_	IN	_	_	_	_	_
20	gene	_	_	NN	_	_	_	_	_
21	silencing	_	_	NN	_	_	_	_	_
22	showed	_	_	VBD	_	_	_	_	_
23	opposite	_	_	JJ	_	_	_	_	_
24	effects	_	_	NNS	_	_	_	_	_
25	,	_	_	,	_	_	_	_	_
26	indicating	_	_	VBG	_	_	_	_	_
27	that	_	_	IN	_	_	_	_	_
28	IRF1	_	_	NNP	_	_	_	_	_
29	positively	_	_	RB	_	_	_	_	_
30	regulates	_	_	VBZ	_	_	_	_	_
31	expression	_	_	NN	_	_	_	_	_
32	of	_	_	IN	_	_	_	_	_
33	type	_	_	NN	_	_	_	_	_
34	III	_	_	CD	_	_	_	_	_
35	IFNs	_	_	NNS	_	_	_	_	_
36	.	_	_	.	_	_	_	_	_

